GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (NAS:NAOV) » Definitions » ROC (Joel Greenblatt) %

NanoVibronix (NanoVibronix) ROC (Joel Greenblatt) % : -363.16% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is NanoVibronix ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. NanoVibronix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -363.16%.

The historical rank and industry rank for NanoVibronix's ROC (Joel Greenblatt) % or its related term are showing as below:

NAOV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -61157.14   Med: -16811.91   Max: -531.31
Current: -531.31

During the past 13 years, NanoVibronix's highest ROC (Joel Greenblatt) % was -531.31%. The lowest was -61157.14%. And the median was -16811.91%.

NAOV's ROC (Joel Greenblatt) % is ranked worse than
84.94% of 850 companies
in the Medical Devices & Instruments industry
Industry Median: -0.965 vs NAOV: -531.31

NanoVibronix's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 56.30% per year.


NanoVibronix ROC (Joel Greenblatt) % Historical Data

The historical data trend for NanoVibronix's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoVibronix ROC (Joel Greenblatt) % Chart

NanoVibronix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13,688.10 -7,502.70 -32,022.47 -1,441.25 -541.94

NanoVibronix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,765.77 -1,134.76 -826.53 -285.60 -363.16

Competitive Comparison of NanoVibronix's ROC (Joel Greenblatt) %

For the Medical Devices subindustry, NanoVibronix's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoVibronix's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoVibronix's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where NanoVibronix's ROC (Joel Greenblatt) % falls into.



NanoVibronix ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.032 + 3.179 + 0.17) - (2.373 + 0 + -4.4408920985006E-16)
=1.008

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.318 + 2.732 + 0.047000000000001) - (2.403 + 0.046 + 4.4408920985006E-16)
=0.648

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of NanoVibronix for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.076/( ( (0.026 + max(1.008, 0)) + (0.012 + max(0.648, 0)) )/ 2 )
=-3.076/( ( 1.034 + 0.66 )/ 2 )
=-3.076/0.847
=-363.16 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NanoVibronix  (NAS:NAOV) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


NanoVibronix ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of NanoVibronix's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoVibronix (NanoVibronix) Business Description

Traded in Other Exchanges
Address
525 Executive Boulevard, Elmsford, New York, NY, USA, 10523
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.
Executives
Christopher M Fashek director 8023 VANTAGE DR, SAN ANTONIO TX 78230
Stephen Russell Brown officer: Chief Financial Officer 18-B NEIL COURT, OCEANSIDE NY 11572
Aurora Cassirer director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Maria Schroeder director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Brian M Murphy director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Michael Ferguson director 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Thomas Mika director TEGAL CORP, 2201 SOUTH MCDOWELL BLVD, PETALUMA CA 94954
Ira A Greenstein director IDT CORP, 520 BROAD STREET, NEWARK NJ 07102
Harold Jacob director, officer: Chief Medical Officer HAADMUR MEBUYON 26, HARNOT, JERUSALEM L3 95403
Martin M Goldstein director C/O NANOVIBRONIX, INC., 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
William Stern director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Jona Zumeris director, officer: VP of Technology 105 MAXESS ROAD, SUITE S124, MELVILLE NY 11747
Miriam W Kelly 10 percent owner P.O. BOX 1443, BROOKLANDVILLE MD 21022